1. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
by Jeffrey E. Lancet, Jorge E. Cortes, Donna E. Hogge, Martin S. Tallman, Tibor J. Kovacsovics, Lloyd E. Damon, Rami Komrokji, Scott R. Solomon, Jonathan E. Kolitz, Maureen Cooper, Andrew M. Yeager, Arthur C. Louie, and Eric J. Feldman
Blood
Volume 123(21):
May 22, 2014
©2014 by American Society of Hematology

2. Twenty-four-month OS and EFS curves.
Twenty-four-month OS and EFS curves. Hazard ratios: (A) 0.83, (B) 0.81, (C) 0.59, (D) 0.88, (E) 0.81, (F) High-risk defined as sAML or adverse cytogenetics or ≥70 years of age. sAML: Secondary AML: a history of antecedent hematologic disorder, usually with MDS, MPN, or history of cytotoxic treatment for non-hematologic malignancy.
Jeffrey E. Lancet et al. Blood 2014;123:
©2014 by American Society of Hematology

3. CONSORT diagram. 7+ 3 = cytarabine and daunorubicin; OS = overall survival.
Jeffrey E. Lancet et al. Blood 2014;123:
©2014 by American Society of Hematology